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Abstract
The X chromosome (chrX) represents one potential source for the ‘‘missing heritability’’ for complex phenotypes, which thus
far has remained underanalyzed in genome-wide association studies (GWAS). Here we demonstrate the benefits of including
chrX in GWAS by assessing the contribution of 404,862 chrX SNPs to levels of twelve commonly studied cardiometabolic and
anthropometric traits in 19,697 Finnish and Swedish individuals with replication data on 5,032 additional Finns. By using a
linear mixed model, we estimate that on average 2.6% of the additive genetic variance in these twelve traits is attributable to
chrX, this being in proportion to the number of SNPs in the chromosome. In a chrX-wide association analysis, we identify three
novel loci: two for height (rs182838724 near FGF16/ATRX/MAGT1, joint P-value=2.71610
29, and rs1751138 near ITM2A,P -
value=3.03610
210) and one for fasting insulin (rs139163435 in Xq23, P-value=5.18610
29). Further, we find that effect sizes
for variants near ITM2A, a gene implicated in cartilage development, show evidence for a lack of dosage compensation. This
observation is further supported by a sex-difference in ITM2A expression in whole blood (P-value=0.00251), and is also in
agreement with a previous report showing ITM2A escapes from X chromosome inactivation (XCI) in the majority of women.
Hence, our results show one of the first links between phenotypic variation in a population sample and an XCI-escaping locus
and pinpoint ITM2A as a potential contributor to the sexual dimorphism in height. In conclusion, our study provides a clear
motivation for including chrX in large-scale genetic studies of complex diseases and traits.
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Introduction
Genome-wide association studies (GWAS) have discovered a
wealth of loci associated with complex phenotypes with almost
5,800 significant associations for more than 500 different
phenotypes reported in the NHGRI GWAS catalog [1] (accessed
August 13, 2013). These GWAS discoveries are, however,
concentrated on the autosomes leaving the sex chromosomes,
especially the relatively large X chromosome (chrX), underrepre-
sented; while chrX contains approximately 5% of genomic DNA,
hence being comparable in size to chromosome 7, and encodes for
more than 1,500 genes, only around 20 unique significantly
associated X-chromosomal loci in total are recorded in the
catalog. For instance, there are hundreds of known autosomal loci
for height, BMI and blood lipids, but only one significant height
locus has been identified in chrX, and this in individuals of African
ancestry, and no X-chromosomal associations for these other
highly polygenic phenotypes have been reported. Nevertheless,
almost 1% of genetic variance in height and BMI has been shown
to be accountable to chrX SNPs [2], demonstrating that common
genetic variation in chrX contributes to complex phenotypes.
A likely explanation for the dearth of association findings in
chrX is that the chromosome is often neglected in GWAS: Wise et
al. recently surveyed all published GWAS from 2010 and 2011
and found that only 33% of these studies had included chrX
analyses [3]. While some association studies have opted for
including chrX, such as recent genetic screens on sex-hormone
binding globulin levels [4] and Grave’s disease [5], removal of
non-autosomal data appears to be a common practice in GWAS
[6,7]. There are many potential reasons for the exclusion of chrX
in GWAS, as outlined by Wise et al [3], a major contributor being
that the analysis pipeline applied for autosomes is not directly
applicable to chrX analyses.
While women carry two copies of chrX, men are hemizygous
for the chromosome. The allele dosages between the sexes are
balanced by random X chromosome inactivation (XCI) that
silences one of the two chromosomes in women, hence requiring
the allele coding for chrX markers to be adjusted accordingly for
the analyses. However, XCI does not evenly cover the whole of
chrX, but approximately 15% of the loci in the chromosome
completely escape from XCI and in further 10% of the sites the
silenced chrX is variably active in women, although the expression
from the inactivated copy of chrX is often lower than from the
active chrX [8]. The incomplete XCI adds another layer of
analytical challenges, yet at the same time it also makes chrX
particularly interesting to study, as the regions of incomplete
dosage compensation are among the genomic contributors to the
differences between gene dosages in men and women. As such,
these loci could partly explain phenotypic sexual dimorphisms and
additionally contribute to the phenotypic characteristics observed
in chrX aneuploidies.
Given the underutilization of chrX data in previous studies and
hence the potential for novel biological discoveries, we aimed at
surveying the contribution of the chromosome to complex traits.
To this end, we expanded the marker set for chrX by imputing the
non-pseudoautosomal region of chrX in almost 25,000 Finnish
and Swedish individuals from seven discovery and one replication
cohort (Table 1) by utilizing the recently released comprehensive
reference panel from the 1000 Genomes Project [9]. We focused
our chrX-wide screen on twelve quantitative anthropometric and
cardiometabolic phenotypes for which hundreds of autosomal, but
no X-chromosomal, loci have been identified in GWAS of
individuals of European ancestry, namely height, body-mass-index
(BMI), waist-hip-ratio (WHR), systolic and diastolic blood pressure
(SPB and DBP), C-reactive protein, fasting insulin and glucose,
total, LDL and HDL cholesterol (TC, LDL-C and HDL-C) and
triglycerides (TG). By using a linear mixed model, we show that
the variation in chrX influences the levels of many of these
complex phenotypes and in an association analysis identify and
replicate three new associated X-chromosomal loci, one for fasting
insulin and two for height, hence demonstrating the value of
assessing chrX associations. Further, we find strong evidence for a
lack of dosage compensation in one of the two associated height
loci by applying a meta-analysis that allows for sex heterogeneity
in effects and by a formal statistical model comparison between the
different dosage compensation models given the observed data.
Results
Genetic variance in chrX contributes to the levels of
many anthropometric and metabolic phenotypes
We first estimated the proportion of variance in each of the
twelve phenotypes accountable jointly to the common and low-
frequency (minor allele frequency (MAF) .1%) SNPs in chrX
using a linear mixed model [2,10] in the study samples for which
the individual-level genotype data were available (Materials and
Methods). ChrX variants were estimated to contribute to the levels
of many of these phenotypes (Table 2): under the model of equal
variance in males and females (see Materials and Methods for
discussion about the models), more than 0.5% of the variance in
height, SBP, HDL-C, fasting glucose and insulin appear to be due
to chrX variation, hence motivating the search for associated
variants in chrX. The highest estimate for X-linked variance
(1.4%, P-value=2.00610
26) was observed for height, a highly
heritable and polygenic phenotype. For the other phenotypes the
statistical significance of the estimates was not overwhelming, a
result of the available sample size and lower trait heritability, but
also the estimates for SBP, HDL-C and fasting insulin were
significantly different (P-value,0.05) from zero. In these four
phenotypes, which showed non-zero X-linked variance, on
average 4.0% (range 2.4%–6.0%) of the estimated whole-genome
genetic variance was attributable to chrX while the corresponding
value over all twelve traits was 2.6%.
Following the work of Yang et al. [2] we calculated the variance
estimates under three different models for dosage compensation,
i.e., equal variance between men and women, full dosage
compensation and no dosage compensation (Table S1). The
differences between the model fit were small (as measured by
likelihood-ratios) and none of the models was consistently favored
above the other two. This is likely due to our sample size being
limited for such comparisons, but may also reflect the differences
in the genetic architecture of the various loci in chrX that
contribute to the variance for each phenotype.
ChrX-wide association analysis identifies three associated
loci
In order to identify X-linked loci contributing to the phenotypic
variance we assessed associations between directly genotyped and
imputed chrX SNPs and the twelve phenotypes across seven
discovery cohorts (N=19,697; Table 1). As the majority of the loci
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consistent with the full dosage compensation model, i.e. we treated
hemizygous men as equivalent to homozygous women (Materials
and Methods). Within each cohort the associations were first
studied separately for males and females using SNPTEST [11] and
the results were subsequently combined in a fixed-effects meta-
analysis in GWAMA [12]. By analyzing the associations of up to
405,411 polymorphic high-quality SNPs we identified three
associated loci (P-value,5610
28): two for height (both in
Xq21.1) and one for fasting insulin (in Xq23) (Table 3, Table
S2, Figure 1). We followed-up these findings in an independent
replication set and found further evidence for association in all
three loci (discovery and replication combined up to N=24,729),
with all lead SNP P-values,6610
29 (Table 3).
In the more strongly associated height locus the associated SNPs
(lead SNP rs1751138, joint, i.e., discovery and replication
combined, P-value=3.03610
210, MAF=0.36) are located ap-
proximately 35 kb upstream of ITM2A (integral membrane
protein 2A), a gene implicated in early cartilage development
[13,14]. We observed that the minor A allele of rs1751138, which
is associated with shorter stature, is also associated with an
increased expression of ITM2A in whole blood (P-val-
ue=6.23610
214, N=513; Materials and Methods), providing
further evidence for ITM2A as a functional candidate gene for this
association. The second region associated with height spans
FGF16, ATRX and MAGT1. The lead SNP (rs182838724, joint P-
value=2.71610
29, MAF=0.30) is intronic within ATRX, a gene
associated with the X-linked alpha thalassaemia mental retarda-
tion syndrome (ATR-X), a rare condition manifesting itself as
profound developmental delay often accompanied by several other
distinct characteristics including skeletal abnormalities in 90% and
short stature in two thirds of the affected individuals [15]. As the
two height lead SNPs map only 2 Mb apart, we confirmed that
the associations are independent of each other by conditioning
the association analysis on the lead SNP of the ITM2A locus. The
conditional analysis did not attenuate the height signal in the
ATRX region, yet here the most associated SNP (rs34979608, joint
P-value=1.52610
29,r
2 with rs182838724=0.91; Table S3,
Figure S1) maps outside ATRX, 4 kb downstream of MAGT1,a
gene encoding a magnesium transporter. Both of the height
associations are present already in childhood (P-value for
Author Summary
The X chromosome (chrX) analyses have often been
neglected in large-scale genome-wide association studies.
Given that chrX contains a considerable proportion of
DNA, we wanted to examine how the variation in the
chromosome contributes to commonly studied pheno-
types. To this end, we studied the associations of over
400,000 chrX variants with twelve complex phenotypes,
such as height, in almost 25,000 Northern European
individuals. Demonstrating the value of assessing chrX
associations, we found that as a whole the variation in the
chromosome influences the levels of many of these
phenotypes and further identified three new genomic
regions where the variants associate with height or fasting
insulin levels. In one of these three associated regions, the
region near ITM2A, we observed that there is a sex
difference in the genetic effects on height in a manner
consistent with a lack of dosage compensation in this
locus. Further supporting this observation, ITM2A has been
shown to be among those chrX genes where the X
chromosome inactivation is incomplete. Identifying phe-
notype associations in regions like this where chrX allele
dosages are not balanced between men and women can
be particularly valuable in helping us to understand why
some characteristics differ between sexes.
Table 1. A summary of the characteristics of the discovery and replication cohorts.
Cohort Full name Sex N Age (years) Height (cm) BMI (kg/m
2)
Discovery
NFBC Northern Finland Birth Cohort 1966 Males 2388 31.060.0 178.266.4 25.263.6
Females 2644 31.060.0 164.866.2 24.264.7
COROGENE The COROGENE Study Males 2441 60.4612.8 176.066.7 27.464.2
Females 1502 62.8613.4 161.666.6 26.965.2
DGI Diabetes Genetics Initiative Males 1534 61.0610.6 174.966.3 27.563.7
Females 1608 62.5610.7 161.766.1 27.864.7
GENMETS Health2000 GenMets Study Males 1000 49.2610.4 176.466.6 27.363.9
Females 1040 52.1611.4 162.766.5 27.265.0
YFS The Cardiovascular Risk in Young Finns Study Males 917 37.665.1 179.766.7 26.864.3
Females 1111 37.665.0 166.066.0 25.365.0
PredictCVD Case control sample from the FINRISK surveys Males 1180 51.5613.0 174.566.8 27.664.3
Females 686 52.2613.4 161.566.5 27.365.3
HBCS Helsinki Birth Cohort Study Males 696 61.462.8 176.965.8 27.564.3
Females 950 61.563.0 163.265.8 27.765.1
Replication
FINRISK Subset from the FINRISK 1997 and 2002 surveys Males 2287 46.8613.4 175.867.0 26.764.1
Females 2745 45.1612.4 162.666.2 26.265.1
N: maximum number of individuals with phenotype and genotype data available; BMI: Body-mass-index; Age, height and BMI are given as mean 6 standard deviation.
doi:10.1371/journal.pgen.1004127.t001
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25, P-value for ATRX=0.00955, N=3287,
subset of two of the study cohorts, ages 8–10; Table S4), but for
the ATRX locus the association appears weaker in children than in
the same individuals in adulthood (beta in childhood=0.059, beta
in adulthood=0.092, P-value for difference in effect sizes=0.043;
Table S4) suggesting additional influence of puberty. In the third
associated locus, the dosage of the minor G allele of rs139163435
(MAF=0.071) was robustly associated with lower levels of fasting
insulin across all cohorts (joint P-value=5.18610
29). The lead
SNP maps to an apparent gene desert: the gene closest to the
association, SLC6A14, a possible candidate gene for X-linked
obesity (OMIM: 300444), lies more than 500 kb away.
Genetic effects near ITM2A suggest a lack of dosage
compensation
Up to 25% of the chrX loci may not be subject to complete
dosage compensation [8], but in these regions also the inactivated
X chromosomes are transcriptionally fully or partially active.
When adopting an allele coding that is consistent with the full
dosage compensation model, as we did in the cohort-level
analyses, the genetic effects in these incompletely dosage
compensated loci are expected to be larger in absolute value in
women than in men. The fixed-effects meta-analysis does not,
however, account for potential sex heterogeneity. Therefore, we
complemented the fixed-effects analysis by performing a meta-
analysis that treats the male and female-specific genetic effects
separately, a so-called sex-differentiated meta-analysis (Materials
and Methods), in order to indicate loci showing incomplete dosage
compensation and to potentially also facilitate the discovery of new
associations.
Allowing for different effect sizes between males and females in
the meta-analysis pinpointed no further loci, yet the ITM2A lead
height SNP was more strongly associated in this sex-differentiated
analysis (joint P-value=3.26610
212; Table 3). Pointing to lack of
dosage compensation, in this locus the allelic effects were estimated
to be more than twice the size in women compared to men when
coding hemizygous men equal to homozygous women (standard-
ized beta in females: 0.093, se: 0.014; beta in males: 0.035, se:
0.009; P-value for the difference in the male and female
effects=2.85610
24; Table 3). For the other two new loci there
was no indication of heterogeneity in the male and female effects
(Table 3). Accordingly, the proportion of variance explained was
approximately twice the size in men compared to women in the
ATRX (0.22% vs. 0.14% for height) and Xq23 (0.51% vs. 0.19%
for fasting insulin) loci, as expected under the model of random
XCI, but not for the ITM2A SNP (0.12% vs. 0.39% for height)
(explained variances calculated under the assumption of full
dosage compensation; Table 3; Materials and Methods). The
observed deviation from the full dosage compensation model in
the ITM2A locus was not driven by differences in allele frequencies
or sample sizes, as these are similar between men and women
(Tables 1 and 3).
Building up evidence for a lack of dosage compensation
in the ITM2A locus
To verify the observation of lack of dosage compensation in the
ITM2A locus for height, we formally investigated how the models
of full dosage compensation and no dosage compensation explain
the data in the three associated loci pinpointed in our chrX-wide
association analysis. To this end we devised a novel application of
a Bayesian model-comparison framework [16] (Materials and
Methods), to quantify the relative support for each of the dosage
compensation models. While the Xq23 and ATRX associations
were highly consistent with full dosage compensation there was
clear evidence towards complete escape from the inactivation in
the ITM2A locus: Assuming that both models are equally probable
a priori, the posterior probabilities for the no dosage compensation
model are 0.07 for rs13916345 in Xq23 (fasting insulin), and 0.18
for rs182838724 near ATRX (height), but 0.99 for rs1751138 near
ITM2A (height) (Figure 2).
As lack of dosage compensation in the ITM2A locus in women
should be reflected in the level of ITM2A expression, given the two
actively transcribed X chromosomes, we evaluated the sex
difference in the level of the ITM2A expression probe that had
earlier showed a significant cis-effect with the lead SNP of the
locus. The average level of ITM2A expression in whole blood was
observed to be higher in women (P-value=0.00251; Figure S2;
Materials and Methods), thus providing further support for
incomplete XCI in this locus.
Discussion
Motivated by the underrepresentation of reported GWAS
discoveries in chrX, we investigated the association of chrX to
twelve anthropometric and cardiometabolic traits in more than
24,500 individuals using a high-resolution map of non-pseudoau-
tosomal chrX SNPs. Our data demonstrate that SNPs in chrX are
associated with many of the studied phenotypes, including the
three novel loci pinpointed in our chrX-wide association analysis.
Additionally, our discovery of lack of dosage compensation for
height near ITM2A not only highlights the value of accounting for
potential sex heterogeneity when assessing chrX associations, but
Table 2. Estimates of the explained variances in the twelve
quantitative phenotypes attributable to chromosome X SNPs
and autosomal SNPs separately using equal variance (EV)
model.
Phenotype N hX (%)
seX
(%) P-value haut (%)
seaut
(%)
Height 14408 1.41 0.41 2.00E-06 52.35 2.41
SBP 9990 1.07 0.52 0.005 16.63 2.98
Fasting glucose 9151 0.84 0.57 0.06 11.15 3.09
HDL-C 11139 0.73 0.42 0.01 30.21 2.85
Fasting insulin 9616 0.68 0.47 0.04 12.66 2.98
TG 11140 0.43 0.4 0.1 19.88 2.72
CRP 9697 0.42 0.47 0.2 11.16 2.89
WHR 12334 0.22 0.34 0.2 12.75 2.36
BMI 14214 0.11 0.31 0.4 25.86 2.25
DBP 9984 0 0.42 0.5 12.5 2.89
LDL-C 11040 0 0.41 0.5 26.43 2.82
TC 11141 0 0.43 0.5 27.21 2.81
The estimates are based on an analysis of the individuals from six Finnish
cohorts using the program GCTA and 217,112 common and low-frequency chrX
SNPs (MAF.1%) directly genotyped or imputed with high-quality (info .0.8)
and 319,445 directly genotyped autosomal SNPs (MAF.1%).
hX: estimate for the proportion of explained variance accountable by the SNPs
in chromosome X in per cent; seX: standard error in per cent for the X
chromosome variance estimate; P-value: P-value for the test of hX=0;h aut:
estimate for the proportion of explained variance accountable by the SNPs in
autosomes in per cent; seaut: standard error in per cent for the autosomal
variance estimate; SBP: systolic blood pressure; HDL-C: high-density lipoprotein
cholesterol; TG: total triglycerides; CRP: C-reactive protein; WHR: waist-hip-ratio;
BMI: body-mass-index; DBP: diastolic blood pressure; LDL-C: low-density
lipoprotein cholesterol; TC: total cholesterol.
doi:10.1371/journal.pgen.1004127.t002
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PLOS Genetics | www.plosgenetics.org 5 February 2014 | Volume 10 | Issue 2 | e1004127Figure 1. A Manhattan plot across all the twelve phenotypes and regional association plots for the three associated loci. A. A
Manhattan plot showing the associations of the X chromosome SNPs to the twelve phenotypes in the discovery analysis. The associated loci (P-
value,5.0610
28) are highlighted with red dots and solid lines. B. A plot of the height associations in the Xq21.1 region showing two separate
association signals. C–E. The association plots for height near ITM2A (C) and height near ATRX (D) and for fasting insulin in Xq23 (E), showing the
association P-values in the discovery analysis. Yellow diamonds indicate the SNPs, which showed the strongest evidence of association in each of the
loci, and purple diamonds and the P-values given in the plots indicate the associations of these lead SNPs in the joint analysis of discovery and
replication data sets. Each circle in the plots indicates a SNP with the color of the circle (in C–E) showing the linkage disequilibrium between the SNP
and the highlighted lead SNP: dark blue (r
2,0.2), light blue (r
2.0.2), green (r
2.0.4), orange (r
2.0.6) and red (r
2.0.8), The r
2 values were calculated
using the genotype data from the COROGENE cohort, and the recombination rate, indicated by the blue lines in the background and the right hand
y-axis, was estimated from the CEU HapMap data. The bottom panels show the genes (RefSeq Genes) and their positions in each locus. In all plots the
dashed red line marks the threshold for genome-wide significance (P-value=5.0610
28).
doi:10.1371/journal.pgen.1004127.g001
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PLOS Genetics | www.plosgenetics.org 6 February 2014 | Volume 10 | Issue 2 | e1004127also manifests that some of the X-linked loci may contribute to
sexual dimorphisms, in this case to the height difference between
men and women.
The contribution of common X-chromosomal SNPs to a few
complex phenotypes have been explored previously: Yang et al.
showed that between 0.57% and 0.82% of the variance in height,
BMI and von Willebrand factor is explained by the SNPs in chrX
[2]. In our study, we extended the estimates to further ten
anthropometric and cardiometabolic phenotypes, and also use a
more comprehensive set of SNPs, and similarly demonstrate that a
small but non-negligible proportion, up to 1.4%, of the total
variance in many of the twelve phenotypes studied appears
attributable to chrX. While the variance estimates for autosomes
have been observed to be proportional to the chromosome length
[2], our estimates for chrX were on average 2.6% of the total
genetic variance estimate, and therefore below what would be
expected based on the proportion of the genomic DNA contained
within chrX, i.e., approximately 5%. However, given the smaller
population size and lower mutation rate, chrX is genetically less
diverse than the autosomes, and indeed our estimates appear to be
more in line with around 3.4% of the SNPs in the 1000 Genomes
reference being X-chromosomal [9] (Figure S3). This implies that
around 3% of all GWAS discoveries could be hidden in chrX and
hence with the inclusion of chrX in GWAS further X-chromo-
somal loci for complex traits will be discovered.
As thus far chrX has only infrequently been included in GWAS
of the twelve traits studied, it is unsurprising that the three loci now
discovered, one for fasting insulin and two for height, represent the
first ones reported in chrX for these phenotypes in European
populations. Two earlier GWAS conducted in individuals of
African ancestry discovered a height locus in Xp22.3 [17,18], yet
the associated lead SNP is monomorphic in Europeans and the
region shows no signal in our analyses. One of the early height
GWAS including mainly European samples showed a suggestive
association (P-value=3610
26) [19] mapping 8.6 kb from the
ITM2A association discovered in our analyses (r
2=0.728 between
the lead SNPs), however, in that study the finding failed to
replicate and thus never reached the formal threshold for
significance.
While further studies are required to elaborate the causative
variants underlying the association with fasting insulin in Xq23, in
both of the height loci there are plausible candidate genes that
could be responsible for the observations. The first height
association spans FGF16, ATRX and MAGT1 in a gene rich
region. Both ATRX and MAGT1 have been implicated in mental
retardation syndromes, and interestingly the syndrome associated
with mutations in ATRX is often accompanied with skeletal
abnormalities and short stature in the affected individuals [15].
Another candidate is FGF16, which is a member of fibroblast
growth factor family shown to play various roles in developmental
processes including morphogenesis. Mouse studies proposed a
crucial role for FGF16 in cardiac morphogenesis [20] and,
recently, nonsense mutations in FGF16 were demonstrated to
associate with congenital limb malformations [21], suggesting the
involvement of the gene in human skeletal development. In the
second height locus, ITM2A is a functional candidate: The
association signal maps just 35 kb upstream of the transcription
start site of ITM2A, a gene known to be involved in cartilage
development [13,14]. Additionally, our eQTL analysis provided
further evidence showing that the height-associated variants in this
locus also influence the expression of ITM2A. Interestingly, high
expression of ITM2A in adipose tissue stem cells has been
Figure 2. Comparison of the dosage compensation models in the three associated loci applying Bayesian framework. A. Separately
estimated effect sizes of the three lead SNPs (dots labeled with rs-numbers) in females (x-axis) and males (y-axis) when female genotypes are coded
{0,1,2} and male genotypes {0,2}. Ellipses show the 95% confidence regions for the estimates. The lines show the regions of the expected values of the
effects under either full dosage compensation (FDC) or no dosage compensation (NDC) models. The associated traits are fasting insulin (INS) and
height (HGT). B. Posterior probability of no dosage compensation (NDC) model at the three lead SNPs when the other candidate is full dosage
compensation model and the two models are equally probable a priori. Labels under bars give the rs-number of the SNP, the associated trait
(INS=fasting insulin or HGT=height) and the height of the bar.
doi:10.1371/journal.pgen.1004127.g002
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PLOS Genetics | www.plosgenetics.org 7 February 2014 | Volume 10 | Issue 2 | e1004127proposed to inhibit the initiation of chondrogenesis in these cells
[22]. As the allele associated with shorter stature associated with
increased expression of ITM2A, this suggests the allelic effect to
height could be mediated through the capacity to generate
cartilage and bone.
Given the unique nature of chrX compared to autosomes, i.e.,
males being hemizygous for the chromosome and the partly
incomplete XCI, which could give rise to sexual dimorphisms, we
analyzed our association data also by accounting for potential
heterogeneity in genetic effects between sexes. This led to the
discovery of considerable sex-difference in the genetic effects for
height near ITM2A, while for the other two associated loci there
was no such evidence. A large-scale scan on 270,000 individuals
for sexual dimorphisms in autosomal genetic effects for various
anthropometric phenotypes identified significant sex differences
only in associations for waist phenotypes and none was observed
for height [23]. Additionally, the few previous height GWAS that
had significant or suggestive discoveries in chrX [17–19] did not,
to our knowledge, evaluate for potential sex heterogeneity in the
chrX associations. Therefore, the sex difference in genetic effects
for height in the ITM2A locus here is likely the first demonstration
of its kind and hence warrants the investigation for potential sex
heterogeneity in associations for other X-linked loci.
The difference in the genetic effects for males and females near
ITM2A appeared fully consistent with no dosage compensation in
this locus. While we cannot completely exclude the possibility that
such a difference can also arise through some other type of sex-by-
SNP interaction effect, we gained further confirmation for the lack
of dosage compensation for height in ITM2A by quantifying the
evidence for the two dosage compensation models in each of the
associated loci using a new model comparison framework.
Additionally, the gene expression data that showed higher
expression of ITM2A in women, as expected if two X chromo-
somes are transcriptionally active in this locus. Similarly,
expression of ITM2A was previously observed to be female-biased
in monocytes and in the same study the cis-eQTL for ITM2A
showed sex heterogeneity [24]. Furthermore, strongly speaking for
the role of impartial silencing of this locus, in a comprehensive
survey into XCI, ITM2A was found to be among the 10% of chrX
genes, which variably escape from inactivation, i.e., are expressed
from the inactivated copy of X (Xi) in a majority of women [8].
For comparison, the expression of ATRX and MAGT1 in the other
height locus (FGF16 was not included in the survey) from Xi is fully
silenced [8].
Given the converging evidence from our association study,
statistical model comparison of the association data, gene
expression data and literature, it seems likely that our observations
of sex heterogeneity in the genetic effects for height near ITM2A
are due to incomplete dosage compensation in this locus.
Therefore, our study likely provides, to the best of our knowledge,
the first link between an XCI-escaping gene and phenotypic
variation in non-syndromic individuals. This discovery has several
plausible implications. As increased expression of ITM2A links
with shorter stature, the greater dosage of ITM2A in women
compared to men may explain some of the substantial sex
difference observed in height. In addition to the sex differences in
the overall expression levels, incomplete dosage compensation also
causes the genetic variation in the population to have different
effects on the trait distribution of males and females. Assuming
that rs1751138, the ITM2A lead SNP, is the causal variant for the
observed height association, we estimate that the observed 36%
frequency of the height decreasing allele accounts for 1.5% of the
current difference in mean height between men and women in the
Finnish population, when compared to a population that was
monomorphic for the major allele at this SNP (Materials and
Methods). Besides contributing to sexual dimorphisms, XCI-
escaping genes are candidates for causing the abnormalities in
chrX aneuploidies. Hence, our findings also highlight ITM2A as a
potential contributor to the height phenotype often observed in
individuals with an unusual number of X chromosomes [25].
To conclude, our findings illustrate the value of including the
chrX in large-scale genetic studies and provide a motivation to
assess the chrX associations in larger sample sizes, particularly for
traits where we estimated chrX to explain part of the trait
variation. We anticipate that such studies will identify further loci
that contribute to the heritability of complex traits, as well as
increase our understanding of their genetic architecture and
underlying biology. As evidenced by our observations in the
ITM2A locus, studying chrX association opens avenues for the
discovery of links between phenotypes and loci that escape from
XCI. Such associations bear potential to bring insights into the
biological bases of sexually dimorphic traits such as complex
diseases with different incidences between males and females.
Materials and Methods
Cohorts
The study included individuals from seven discovery cohorts:
The Northern Finland Birth Cohort 1966 (NFBC1966), The
Cardiovascular Risk in Young Finns Study (YFS), The COR-
OGENE Study (COROGENE), Helsinki Birth Cohort Study
(HBCS), the Health 2000 GenMets Study (GenMets), the Diabetes
Genetics Initiative (DGI) and a prospective cardiovascular disease
(CVD) case-control sample from the FINRISK collections
(PredictCVD). In the replication stage a further subset of
individuals from the FINRISK collections (FR) was included. A
summary of the cohort characteristics is given in Table 1. All
participants gave an informed consent and the data was de-
identified for all analyses.
NFBC1966 is a birth cohort study of children born in 1966 in
the two northernmost provinces of Finland originally designed to
focus on factors affecting pre-term birth, low birth weight, and
subsequent morbidity and mortality [26]. The blood sample for
the DNA extraction and all phenotype data (except the childhood
height measurements) used in the present study were collected at a
follow-up visit when the participants were 31 years of age. The
COROGENE cohort includes acute coronary syndrome patients
who underwent coronary angiogram between June 2006 and
March 2008 in the Helsinki University Central Hospital [27] and
matched controls from the Helsinki-Vantaa region participants of
FINRISK 1997, 2002, and 2007 surveys performed in Finland
every five years since 1972 [28]. In the current study, the
COROGENE cases were only included in the analyses of height
and body-mass-index. The DGI sample consists of individuals
from Sweden and Finland and was originally designed to identify
loci associated with type 2 diabetes (T2D) [29]. The sample
consists of patients with T2D; gender, BMI, age and geograph-
ically matched controls and discordant sibships. The current
analysis was performed on 3142 individuals, including all
individuals from the original analysis and individuals previously
excluded after having been identified as belonging to pairs of
samples identified as cryptic first degree relatives [29]. GenMets is
a subset from the Health 2000 survey collected in 2000–2001 to
obtain information on the most important public health problems
in Finland [30]. The cohort includes metabolic syndrome cases
and their matched controls aged 30 years and above. YFS is a
longitudinal follow-up study of children and adolescents from all
around Finland initiated in 1980 to study the cardiovascular risk
New Loci for Height and Fasting Insulin in chrX
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study is from the 27-year follow-up when the participants were 30–
45 years of age. The PredictCVD study comprises of incident
cardiovascular disease cases and matched controls selected from
the 1992, 1997, 2002 and 2007 FINRISK surveys [28]. For the
analyses of the current study, the 96 individuals included and
genotyped in both COROGENE and PredictCVD samples were
excluded from the COROGENE data set. The FR sample used
for replication includes a random, yet non-overlapping with
COROGENE and PredictCVD, subset of individuals from
FINRISK surveys from 1997 and 2002.
Genotyping and imputation
The following genotyping arrays were used for genotyping the
study cohorts: Illumina 370K array for NFBC1966, Illumina
610K array for COROGENE and GenMets, custom generated
Illumina 670K array for YFS and HBCS, Illumina 770K array for
PredictCVD, Illumina HumanCoreExome-12v1-0 for FR and
Affymetrix GeneChip Human Mapping 500K Array set for DGI.
The quality control procedures included removing closely related
individuals (PI_HAT .0.1) by analyzing pairwise IBD relation-
ships for all individuals in five Finnish discovery cohorts together
and have been described previously in detail [29,32]. The
imputation of non-pseudoautosomal chrX variants into the study
cohorts was performed on the cleaned data in each cohort using
IMPUTE version 2.2.2 [33,34]. The reference panel used in the
imputation was the integrated variant set release (v3) released in
March 2012 (http://mathgen.stats.ox.ac.uk/impute/
data_download_1000G_phase1_integrated.html). The data were
split into genomic regions of ,5 Mb (with 250 kb (DGI) or 1 Mb
(other cohorts) buffer region), using effective population size of
20000 (DGI) or 11418 and k value of 80.
Phenotype adjustments
Within each cohort, all twelve phenotypes were adjusted for
males and females separately using age (not in NFBC1966) and ten
first principal components as covariates. Additionally, WHR and
blood pressure measurements were adjusted for BMI. The
residuals from the linear regression were inverse normal
transformed to have mean 0 and standard deviation 1, and the
normalized residuals were then used as phenotypes in the variance
estimate and association analyses. In cohorts where the informa-
tion was available, individuals on lipid-lowering medication were
excluded prior the covariate adjustment for the blood lipids (TC,
TG, LDL-C and HDL-C), blood-pressure medication was an
exclusion criterion for systolic and diastolic blood pressure and
diabetes medication for glucose and insulin. Non-fasting individ-
uals were excluded from the analysis of glucose and insulin, and
pregnant women were only included in the analysis of CRP and
height. All phenotype adjustments and data normalization were
done in STATA/SE 12.1 or R (version 2.11.1). The sample size
for each phenotype in the discovery cohorts, i.e., the number of
individuals with both genotype and phenotype information, are
given in Table S5.
Estimation of the variance explained by the X
chromosome and the autosomes
We estimated how much phenotypic variance a panel of
217,112 high quality SNPs from chrX (IMPUTE2 info .0.8,
MAF .0.01) explain using the linear mixed model approach
implemented in GCTA (v.1.13) [10]. This analysis included six of
the seven discovery cohorts (NFBC1966, COROGENE, Gen-
Mets, YFS, HBCS and PredictCVD) for which we had access to
the individual genotype data. Following the work of Yang et al.
[2], we applied three models for dosage compensation: full dosage
compensation (FDC), no dosage compensation (NDC) and equal
variance in both sexes (EV). However, none of the models was
consistently favored over the other two across the traits (Table S1).
In the main text we report the variance estimates from the EV
model because those best capture the average genetic contribution
of chrX to the population: in FDC and NDC models the variances
between males and females are different and for both models the
mean of the sex-specific variances is close to the single value given
by the EV model in our data. Furthermore, since the traits have
been normalized to have a variance of 1 within each sex, the
models that assume different genetic variance between the sexes
(namely FDC and NDC) should also allow different residual
variances between the sexes but this has not been implemented in
GCTA (v.1.13). We report the results from all three models using
imputed SNPs in Table S1.
For a comparison, we also estimated the genetic variances using
9,517 directly genotyped SNPs in chrX but did not find notable
differences from the results with the imputed data (Table S6). For
another comparison, we estimated the variance explained by the
319,445 directly genotyped SNPs with MAF.0.01 in the
autosomes (Table 2). If the variants contributing to the traits were
uniformly distributed across the genome, then we would expect
that chrX genetic variance is about 3% of the autosomal genetic
variance, as about 3% of the genetic variation in our data is in the
X chromosome. Figure S3 plots estimated autosomal genetic
variance against chrX one.
All mixed model analyses excluded individuals in such a way
that none of the remaining pairs of individuals had an estimated
relatedness coefficient r .0.05 and the same trait values were
used as with the association analyses. For comparison, the analyses
were also carried out by using r=0.025 as the relatedness cut-off
(Table S7).
Chromosome X-wide association analyses
The associations between variants and phenotypes were tested
for all available genotyped or imputed SNPs in chrX separately for
men and women in each cohort encoding genotypes {0,2} in men
and {0,1,2} in women, i.e., assuming that one of the two X
chromosomes in women is fully inactivated. In DGI the analysis
was performed using a linear mixed model that can account for
sample structure, as implemented in EMMAX [35]. In other
cohorts the analyses were performed in SNPTEST [11] (version
2.4.0) assuming an additive genetic model and using expected
genotype counts. In each cohort the results were filtered prior the
meta-analysis to include only good-quality variants (SNPTEST
info in women .0.4) and variants with more than three copies of
the minor allele (minor allele count in women .3) resulting in
between 323,564 and 383,337 variants per cohort in the discovery
set.
The cohorts and genders were combined in a fixed-effects
(inverse variance weighted) meta-analysis and in a sex-differenti-
ated meta-analysis, which combines the results allowing for the
allelic effects to differ between men and women and also conducts
a meta-analysis separately for the results from men and from
women, both meta-analysis options implemented in GWAMA
[12]. Genomic control was applied for the association results of
each study to account for P-value inflation arising from residual
population structure in the data or other confounding factors. The
meta-analysis summary was also corrected with the genomic
control lambda for those phenotypes where there was indication of
inflation (lambda .1.0): The genomic control lambdas for the
twelve phenotypes were between 0.94–1.13 in the discovery
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were further filtered to include only the SNPs for which the
association result was available from at least two of the input files,
hence association results were available for up to 405,411 SNPs.
Adopting the genome-wide significance P-value threshold, P-
value,5610
28, three loci showed significant associations in the
discovery analysis. In these associated loci the lead SNPs were
imputed with high quality (imputation info .0.80) in all cohorts.
Height associations in childhood
To investigate whether the observed associations with height
near ITM2A and ATRX are present already in pre-puberty, the
association of the chrX SNPs with childhood height was studied in
a subset of individuals from NFBC1966 and YFS cohorts
(N(males)=1204 and N(females)=1189 in NFBC1966;
N(males)=417 and N(females)=478 in YFS) who had height
measurements available both from pre-puberty (ages 8–10 years
for NFBC1966 and 9 years for YFS) and adulthood. The height
measurements were adjusted for age (in NFBC1966) and ten first
principal components, the residuals were inverse normal trans-
formed and subsequently the association of the SNP dosage with
the transformed residuals was studied in SNPTEST using an
additive model of association. The SNP-phenotype associations for
the two height measurements were studied in both cohorts,
separately for the genders, and the results were combined in a
fixed-effects and a sex-differentiated meta-analysis using GWAMA
applying genomic control correction. The association results for
the height lead SNPs with childhood and adulthood height in these
individuals are given in Table S4.
Cis-eQTL analysis of the associated regions
A subset of the COROGENE cohort (N=513) had both
genome-wide SNP data and gene expression data from whole
blood, assayed using Illumina HumanHT-12v3 Expression
BeadChips, available, as described previously [36]. The associa-
tions between the three lead SNPs and all gene expression probes
within 1 Mb of the SNPs was studied in SNPTEST using an
additive model of association. For the one significantly associated
expression probe (ITM2A/ILMN_2076600) we further evaluated
whether the level of expression was different between the sexes by
comparing the unadjusted expression in males and females using
Student’s t-test in R.
Variance explained by individual loci in chromosome X
As males carry only one copy of the X chromosome, the
genotype variances of the SNPs in the non-pseudoautosomal
region of chrX differ between women and men. Assuming the
model of complete inactivation of one the X chromosomes in
women, and hence coding the X-linked alleles {0,2} in men and
{0,1,2} in women, the genotype variance in men is twice that in
women: 2P(1-P) for females and 4P(1-P) males, where P denotes
the allele frequency of the SNP. Thus, the estimation of the
variance explained from the meta-analysis summary statistics
should be evaluated for the genders separately using the formulas
2P(1-P)bF
2 for women and 4P(1-P)bM
2 for men, where bF and bM
denote the standardized effect sizes in women and men,
respectively.
Comparison of dosage compensation models
We applied a Bayesian framework [37] to compare full
dosage compensation (FDC) and no dosage compensation
(NDC) models at the top SNPs of the three associated regions.
We used the estimated effect sizes bF (allelic effect in females)
and bM (effects in males when two genotypes are coded 0 and 2)
together with their standard errors to approximate the likelihood
function as in [16]. The two models differ in their prior
specification:
FDC: bF,N(0, s
2), bM,N(0, s
2) and cor(bF,bM)=1
NDC: bF,N(0, s
2), bM,N(0, 0.25 s
2) and cor(bF,bM)=1
Where s
2, the variance of the prior effect size in females,
depends on the allele frequency of the SNP and is chosen so that
with 95% probability the studied SNP explains less than 1% of the
variance of the trait. Intuitively, according to the FDC model
bF=b M whereas according to the NDC model bF=2b M. Bayes
factors between the two models can be computed using the
approximate likelihood approach [16] and the posterior proba-
bilities of the NDC model are shown in Figure 2 under the
assumption that each model is equally likely a priori.
Effect of lack of dosage compensation on sex difference
in mean trait value
Suppose that each copy of the minor allele (‘a’ with frequency fa)
at a particular SNP on chrX causally affects the trait value by ‘b’
both in males and in females, i.e., there is no dosage compensa-
tion. To simplify notation, we assume that the mean trait value of
males with genotype ‘A’ is the same as the mean trait value in
females with genotype ‘AA’, and denote this mean by ‘m’. The
overall mean trait values in males, ‘mM’, and in females, ‘mF’, are
mM=(12fa)Nm + faN(m+b)=m + faNb, and
mF=f AANm + fAaN(m+b) + faaN(m+2b)=m + (fAa+2faa)Nb=m +
2faNb
The difference in the sex-specific means is
mM 2 mF=m+ faNb 2 (m + 2faNb)=2 faNb
So the effect of allele ‘a’ is either to increase (if b,0) or decrease
(if b.0) the male-female difference in the mean trait value by
|faNb|, compared to the situation where only allele ‘A’ was present
in the population.
Application to rs1751138, the lead SNP of the association near
ITM2A:
b=20.555 cm (se=0.0734 cm). This is a fixed-effects estimate
of the allelic effects in quantile normalized height in females
20.092559 (0.013934) and males 20.071802 (0.019274), multi-
plied by an estimate of the standard deviation of height in Finland,
6.5 cm.
Thus by introducing the minor allele (A) with frequency
fa=0.36 in the population, the male-female difference in mean
height increases by 0.36*0.555 cm=0.20 cm. As the mean
difference in height between the sexes in Finland is about
13.7 cm, the variation at this SNP accounts for 0.20 cm/
13.7 cm=0.0146<1.5% of that difference.
Supporting Information
Figure S1 Regional association plots of the associations in the
two height loci after conditioning the association analysis on
rs1751138, the lead associated SNP in the ITM2A height locus. A:
The region near FGF16, ATRX and MAGT1. The lead associated
SNP in this analysis, rs34979608, is highlighted with diamonds,
the yellow diamond indicating the association in the discovery
analysis and the purple diamond and text the association in the
joint analysis of discovery and replication cohorts. The yellow 6
indicates the association of the SNP that was most associated with
height in this region in the discovery meta-analysis, i.e., before the
conditional analysis (P-values 3.02610
27 and 2.80610
28 in the
conditional analysis using the discovery cohorts and both
discovery and replication data, respectively). B: The region near
ITM2A. No association with height remains in this region in the
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the color of the circle shows the linkage disequilibrium, r
2,o ft h e
SNP to the lead associated SNP in each region, rs34979608 in A
and rs1751138 in B: dark blue (r
2,0.2), light blue (r
2.0.2), green
(r
2.0.4), orange (r
2.0.6) and red (r
2.0.8). The correlation
structure between the SNPs was calculated from Finnish data
using the genotypes from the COROGENE cohort. The light
blue line in the background and the right hand y-axis show the
recombination rate in the region as calculated from HapMap
CEU data.
(PDF)
Figure S2 Boxplots of ITM2A expression in men and women.
The levels of whole blood ITM2A expression visualized using
boxplots separately for men (blue) and women (orange) in the
individuals of COROGENE cohort (N=513) for whom expres-
sion data was available. The mean expression level is higher in
women (P-value=0.00251) providing support for incomplete
dosage compensation between men and women in the ITM2A
locus.
(PDF)
Figure S3 Comparison of the phenotypic variances attributable
to chromosome X variants (y-axis) and autosomal variants (x-axis).
The dashed line is y=0.03x and shows the region of the expected
values of the points under the assumption that the genetic effects
are small and uniformly distributed across the genome and that
the X chromosome contains about 3% of all genetic variation. The
dotted lines show the standard errors of the estimates. The traits
are TC: total cholesterol; LDL-C: low-density lipoprotein
cholesterol; HDL-C: high-density lipoprotein cholesterol; TG:
total triglycerides; CRP: C-reactive protein; BMI: body-mass-
index; WHR: waist-hip-ratio; SBP: systolic blood pressure; DBP:
diastolic blood pressure; HGT: height; GLK: fasting glucose; INS:
fasting insulin.
(PNG)
Table S1 Estimates of the phenotypic variance attributable to
217,112 imputed and genotyped chrX SNPs using three different
dosage compensation models.
(XLS)
Table S2 Association results in each discovery cohort for the
lead SNPs in the three associated loci (rs1751138 near ITM2A and
rs182838724 near FGF16, ATRX and MAGT1 for height and
rs139163435 in Xq23 for fasting insulin).
(XLS)
Table S3 Lead associations in the height locus near FGF16,
ATRX and MAGT1 after conditioning the association analysis on
the lead SNP of the ITM2A locus, rs1751138.
(XLS)
Table S4 Associations of the most associated SNPs in the two
height loci with height in childhood (age 8–10) and adulthood in a
subset of the study subjects from two cohorts (NFBC1966 and
YFS) for whom childhood height measurements were available.
(XLS)
Table S5 Sample sizes for the twelve phenotypes in the
discovery cohorts.
(XLS)
Table S6 Estimates of the phenotypic variance attributable to
9,517 directly genotyped chrX SNPs using three different dosage
compensation models.
(XLS)
Table S7 Estimates of the phenotypic variance attributable to
217,112 imputed and genotyped chrX SNPs using three different
dosage compensation models using a threshold of 0.025 to remove
related individuals.
(XLS)
Table S8 Genomic control lambdas for the twelve phenotypes in
the X chromosome-wide meta-analyses of the discovery cohorts.
In cases where lambda .1, the meta-analysis results were
corrected using the lambda statistic.
(XLS)
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